logo
Breast cancer risk cut by 35% in new clinical trial

Breast cancer risk cut by 35% in new clinical trial

New York Post31-05-2025
Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday.
The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.
After a median follow-up of 14 months, patients treated with Trodelvy, a so-called antibody-drug conjugate, and Keytruda went 11.2 months without their cancer progressing, a measure known as progress-free survival. That compared with PFS of 7.8 months for those given the standard treatment of chemotherapy and Keytruda, researchers said.
Advertisement
3 Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.
REUTERS
Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to full results of the study presented at the American Society of Clinical Oncology scientific meeting in Chicago. The researchers said patients are still being followed to see if the regimen has an impact on overall survival.
Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 – the protein targeted by drugs like Keytruda – had met its goal.
Advertisement
The findings suggest that the combination of Trodelvy and Keytruda 'will likely become a new front-line standard of care in this setting,' Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert, said in a statement.
ASCO estimates that about 10% of breast cancers in the United States are triple-negative.
3 Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to the results.
Peakstock – stock.adobe.com
That tends to be more difficult to treat than hormone-sensitive subtypes, because it does not have the common biomarkers used to guide treatment, the tumors are often larger, and the recurrence rate is high.
Advertisement
The medical group said that about 40% of triple-negative breast cancers are also PD-L1 positive, making them candidates for Keytruda.
Antibody-drug conjugates like Trodelvy are designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy cells than chemotherapy.
3 Gilead is also conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.
REUTERS
Serious side effects for Trodelvy included neutropenia, a condition caused by cancer treatments that lower levels of infection-fighting white blood cells, reported in 43% of patients, and diarrhea in 10%. In the chemotherapy group, the incidence of neutropenia was 45%, while 16% of patients had anemia and 14% had low blood platelet counts.
Advertisement
Trodelvy is already approved for patients with advanced triple-negative breast cancer who had two or more prior therapies, and for previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer.
Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck concludes SpringWorks acquisition for $3.4bn
Merck concludes SpringWorks acquisition for $3.4bn

Yahoo

time3 hours ago

  • Yahoo

Merck concludes SpringWorks acquisition for $3.4bn

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary closing conditions. The merger, announced in April 2025, will positively impact Merck's financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. Merck will add two SpringWorks' products targeting rare tumours with limited treatment options. Ogsiveo (nirogacestat) is approved by the Food and Drug Administration (FDA) for adults with progressing desmoid tumours requiring systemic treatment. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) also recommended its approval in June 2025. Gomekli (mirdametinib) is approved by the FDA for neurofibromatosis type 1 (NF1)-related symptomatic plexiform neurofibromas (PN) in adults and children aged two years and above deemed unsuitable for complete resection. Mirdametinib also received a positive opinion from CHMP in May 2025. Merck executive board chair and CEO Belén Garijo stated: 'The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck as a globally diversified science and technology powerhouse. 'This is the largest acquisition we have made for our healthcare business sector in nearly 20 years, marking an exciting new chapter. Furthermore, we remain committed to identifying mergers and acquisitions opportunities across our three business sectors, with a focus on life science, prioritising strategic fit, financial robustness and long-term value creation.' The integration of SpringWorks' portfolio enhances Merck's strategic focus on developing treatments for rare tumours, including commercialisation rights for pimicotinib developed by Abbisko Therapeutics aimed at tenosynovial giant cell tumour patients. As a result of this transaction, trading of SpringWorks shares on Nasdaq has ceased, with shareholders receiving $47 per share in cash from Merck. "Merck concludes SpringWorks acquisition for $3.4bn" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

German pharma giant Merck takes over US cancer specialist
German pharma giant Merck takes over US cancer specialist

Yahoo

time11 hours ago

  • Yahoo

German pharma giant Merck takes over US cancer specialist

German pharmaceutical giant Merck has completed a €3 billion ($3.5 billion) takeover of US biopharmaceutical company Springworks Therapeutics, the firm confirmed on Tuesday. With the acquisition, Merck intends to build a business around the treatment of rare tumours, where it sees a therapeutic gap. "Many of those affected are still young and face a lengthy treatment path with an uncertain outcome and only limited treatment options," said Danny Bar-Zohar, head of Merck's pharmaceuticals division. Springworks already has a drug approved in the US for the treatment of progressive soft tissue tumours and for a disease with benign tumours on the skin or nerves. Both drugs could soon also be given the green light in the EU. The deal is the largest for Merck's pharmaceutical unit in nearly 20 years. Merck chief executive Belén Garijo described the acquisition as "pioneering." Garijo told dpa that both Springworks therapies could become blockbuster drugs in the future, meaning that each could generate sales of at least $1 billion per year for Merck. The acquisition of Springworks is a "transformative step," the manager explained. It will allow Merck to expand its business in the US, focus more on rare diseases and accelerate growth. At the same time, Garijo did not rule out further acquisitions, above all in the business with products for pharmaceutical research and drug manufacturing. Merck's pharmaceuticals division has recently shown solid growth. However, the group is under pressure to bring new drugs onto the market. Several promising drugs that were supposed to bring billions into Merck's coffers have failed in clinical trials. The acquisition of Springworks, the largest in the pharma division since the purchase of the Swiss group Serono in 2007 for €10.3 billion, is expected to directly increase Merck's sales. Merck's last major acquisition was the US semiconductor supplier Versum Materials in 2019, worth around €5.8 billion. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Over 170 charities call for end to deadly new Gaza aid distribution system
Over 170 charities call for end to deadly new Gaza aid distribution system

Yahoo

time14 hours ago

  • Yahoo

Over 170 charities call for end to deadly new Gaza aid distribution system

By Olivia Le Poidevin GENEVA (Reuters) -More than 170 non-governmental organisations called on Tuesday for a U.S.- and Israeli-backed food aid distribution scheme in Gaza to be dismantled over concerns it is putting civilians at risk of death and injury. More than 500 people have been killed in mass shootings near aid distribution centres or transport routes guarded by Israeli forces since the Gaza Humanitarian Foundation started operating in late May, according to medical authorities in Gaza. The GHF uses private U.S. security and logistics companies to get supplies into Gaza, largely bypassing a U.N.-led system that Israel says had let militants divert aid. The United Nations has called the plan "inherently unsafe" and a violation of humanitarian impartiality rules. As of early afternoon in Geneva on Tuesday, where the joint declaration was released, 171 charities had signed on to the call for countries to press Israel to halt the GHF scheme and reinstate aid coordinated through the United Nations. "Palestinians in Gaza face an impossible choice: starve or risk being shot while trying desperately to reach food to feed their families," the statement said. Groups signing it included Oxfam, Doctors Without Borders, Save the Children, the Norwegian Refugee Council and Amnesty a response, the GHF told Reuters it had delivered more than 52 million meals in five weeks and said other humanitarian groups had "nearly all of their aid looted". "Instead of bickering and throwing insults from the sidelines, we would welcome other humanitarian groups to join us and feed the people in Gaza," the GHF told Reuters. Doctors Without Borders told reporters in an online press briefing on Tuesday that within the last month two of its small primary health centres had received 22 dead and 548 wounded people. Those who died had received fatal wounds to the chest and in abdomen. "They are not warning shots. They are shots directed towards the people," said Aitor Zabalgogeazkoa, one of MSF's emergency coordinators in Gaza. In more than 50% of the mass casualty incidents near food distribution sites, children have been shot and killed, said Rachel Cummings, Humanitarian Director for Save the Children in Gaza. "Children have told us they want to die... to be with their mother or father who have been killed. They want to be in paradise because there is food and water," said Cummings. The Israeli military acknowledged on Monday that Palestinian civilians have been harmed at aid distribution centres in Gaza, saying that Israeli forces had been issued new instructions following what it called "lessons learned". Israel has repeatedly said its forces operate near the centres in order to prevent the aid from falling into the hands of Palestinian Hamas militants.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store